Clinical Trials

A First-in-Human Study of Repeat Dosing with REGN2810, A Monoclonal, Fully Human Antibody to Programmed Death – 1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies


Study ID
Regeneron R2810-ONC-1423

NCT Number
NCT02383212 (Click on the NCT number for more information about the trial)

Research Study Number
00005865

Principle Investigator
Dr. Martin Gutierrez

Phase
I

Sponsor
Regeneron


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now